APO Research
Talk to an analyst

APO RESEARCH · REPORT

Covid-19 Vaccine

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

Selected research

Market Outlook & Growth Opportunities

Global Covid-19 Vaccine Market Outlook and Growth Opportunities 2026

28 December 2025190 pages

Choose your research edition.

Industry ResearchCovid-19 Vaccine Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Covid-19 Vaccine Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Covid-19 Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Covid-19 Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Covid-19 Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 53.8% in 2026, Europe is the second largest consumption place with the consumption market share of 24.61% in 2026.

This report provides an overview of the global Covid-19 Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Covid-19 Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Covid-19 Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Covid-19 Vaccine market.

Covid-19 Vaccine Segment by Company

Moderna

CanSino Biologicals

Inovio Pharmaceuticals

Shenzhen Geno-Immune Medical Institute

GlaxoSmithKine

Pfizer

Johnson＆Johnson

Heat Biologics

Sanofi

Covid-19 Vaccine Segment by Type

DNA

Non-replicating Viral Vector

Protein Subunit

RNA

Others

Covid-19 Vaccine Segment by Application

Adults

Children

Covid-19 Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Covid-19 Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Covid-19 Vaccine key companies, revenue, market share, and recent developments.

3. To split the Covid-19 Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Covid-19 Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Covid-19 Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Covid-19 Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Covid-19 Vaccine industry.

Chapter 3: Detailed analysis of Covid-19 Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Covid-19 Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Covid-19 Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Covid-19 Vaccine Industry Trends Table 2. Covid-19 Vaccine Industry Drivers Table 3. Covid-19 Vaccine Industry Opportunities and Challenges Table 4. Covid-19 Vaccine Industry Restraints Table 5. Global Covid-19 Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Covid-19 Vaccine Revenue Share by Company (2021-2026) Table 7. Global Covid-19 Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Covid-19 Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Covid-19 Vaccine Company, Product Type & Application Table 10. Global Covid-19 Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Covid-19 Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DNA Table 15. Significant Companies of Non-replicating Viral Vector Table 16. Significant Companies of Protein Subunit Table 17. Significant Companies of RNA Table 18. Significant Companies of Others Table 19. Global Covid-19 Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Covid-19 Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Covid-19 Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Covid-19 Vaccine Sales Value Share by Type (2021-2026) Table 23. Global Covid-19 Vaccine Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Adults Table 25. Significant Companies of Children Table 26. Global Covid-19 Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Covid-19 Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Covid-19 Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Covid-19 Vaccine Sales Value Share by Application (2021-2026) Table 30. Global Covid-19 Vaccine Sales Value Share by Application (2027-2032) Table 31. Global Covid-19 Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Covid-19 Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Covid-19 Vaccine Sales Value Share by Region (2021-2026) Table 34. Global Covid-19 Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Covid-19 Vaccine Sales Value Share by Region (2027-2032) Table 36. Global Covid-19 Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Covid-19 Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Covid-19 Vaccine Sales Value Market Share by Country (2021-2026) Table 39. Global Covid-19 Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Covid-19 Vaccine Sales Value Market Share by Country (2027-2032) Table 41. Moderna Company Information Table 42. Moderna Business Overview Table 43. Moderna Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Moderna Covid-19 Vaccine Product Portfolio Table 45. Moderna Recent Development Table 46. CanSino Biologicals Company Information Table 47. CanSino Biologicals Business Overview Table 48. CanSino Biologicals Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. CanSino Biologicals Covid-19 Vaccine Product Portfolio Table 50. CanSino Biologicals Recent Development Table 51. Inovio Pharmaceuticals Company Information Table 52. Inovio Pharmaceuticals Business Overview Table 53. Inovio Pharmaceuticals Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio Table 55. Inovio Pharmaceuticals Recent Development Table 56. Shenzhen Geno-Immune Medical Institute Company Information Table 57. Shenzhen Geno-Immune Medical Institute Business Overview Table 58. Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio Table 60. Shenzhen Geno-Immune Medical Institute Recent Development Table 61. GlaxoSmithKine Company Information Table 62. GlaxoSmithKine Business Overview Table 63. GlaxoSmithKine Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. GlaxoSmithKine Covid-19 Vaccine Product Portfolio Table 65. GlaxoSmithKine Recent Development Table 66. Pfizer Company Information Table 67. Pfizer Business Overview Table 68. Pfizer Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pfizer Covid-19 Vaccine Product Portfolio Table 70. Pfizer Recent Development Table 71. Johnson＆Johnson Company Information Table 72. Johnson＆Johnson Business Overview Table 73. Johnson＆Johnson Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Johnson＆Johnson Covid-19 Vaccine Product Portfolio Table 75. Johnson＆Johnson Recent Development Table 76. Heat Biologics Company Information Table 77. Heat Biologics Business Overview Table 78. Heat Biologics Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Heat Biologics Covid-19 Vaccine Product Portfolio Table 80. Heat Biologics Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Covid-19 Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Sanofi Covid-19 Vaccine Product Portfolio Table 85. Sanofi Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Covid-19 Vaccine Product Image Figure 2. Global Covid-19 Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Covid-19 Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Covid-19 Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DNA Image Figure 8. Non-replicating Viral Vector Image Figure 9. Protein Subunit Image Figure 10. RNA Image Figure 11. Others Image Figure 12. Global Covid-19 Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Covid-19 Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Covid-19 Vaccine Sales Value Share by Type (2021-2032) Figure 15. Adults Image Figure 16. Children Image Figure 17. Global Covid-19 Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Covid-19 Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Covid-19 Vaccine Sales Value Share by Application (2021-2032) Figure 20. Global Covid-19 Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Covid-19 Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Covid-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Covid-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Covid-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Covid-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Covid-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Covid-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Covid-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Covid-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Covid-19 Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Covid-19 Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Covid-19 Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • DNA
  • Non-replicating Viral Vector
  • Protein Subunit
  • RNA
  • Others
Applications
  • Adults
  • Children
Companies covered
  • Moderna
  • CanSino Biologicals
  • Inovio Pharmaceuticals
  • Shenzhen Geno-Immune Medical Institute
  • GlaxoSmithKine
  • Pfizer
  • Johnson＆Johnson
  • Heat Biologics
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Covid-19 Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Covid-19 Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Covid-19 Vaccine Market Dynamics
  1. 2.1 Covid-19 Vaccine Industry Trends
  2. 2.2 Covid-19 Vaccine Industry Drivers
  3. 2.3 Covid-19 Vaccine Industry Opportunities and Challenges
  4. 2.4 Covid-19 Vaccine Industry Restraints
3 Covid-19 Vaccine Market by Company
  1. 3.1 Global Covid-19 Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Covid-19 Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Covid-19 Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Covid-19 Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Covid-19 Vaccine Company Product Type and Application
  6. 3.6 Global Covid-19 Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Covid-19 Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Covid-19 Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Covid-19 Vaccine Market by Type
  1. 4.1 Covid-19 Vaccine Type Introduction
  2. 4.1.1 DNA
  3. 4.1.2 Non-replicating Viral Vector
  4. 4.1.3 Protein Subunit
  5. 4.1.4 RNA
  6. 4.1.5 Others
  7. 4.2 Global Covid-19 Vaccine Sales Value by Type
  8. 4.2.1 Global Covid-19 Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Covid-19 Vaccine Sales Value by Type (2021-2032)
  10. 4.2.3 Global Covid-19 Vaccine Sales Value Share by Type (2021-2032)
5 Covid-19 Vaccine Market by Application
  1. 5.1 Covid-19 Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Covid-19 Vaccine Sales Value by Application
  5. 5.2.1 Global Covid-19 Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Covid-19 Vaccine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Covid-19 Vaccine Sales Value Share by Application (2021-2032)
6 Covid-19 Vaccine Regional Value Analysis
  1. 6.1 Global Covid-19 Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Covid-19 Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Covid-19 Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Covid-19 Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Covid-19 Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Covid-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Covid-19 Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Covid-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Covid-19 Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Covid-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Covid-19 Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Covid-19 Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Covid-19 Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Covid-19 Vaccine Sales Value Share by Country, 2025 VS 2032
7 Covid-19 Vaccine Country-level Value Analysis
  1. 7.1 Global Covid-19 Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Covid-19 Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Covid-19 Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Covid-19 Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Covid-19 Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Covid-19 Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Covid-19 Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Moderna
  2. 8.1.1 Moderna Company Information
  3. 8.1.2 Moderna Business Overview
  4. 8.1.3 Moderna Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Moderna Covid-19 Vaccine Product Portfolio
  6. 8.1.5 Moderna Recent Developments
  7. 8.2 CanSino Biologicals
  8. 8.2.1 CanSino Biologicals Company Information
  9. 8.2.2 CanSino Biologicals Business Overview
  10. 8.2.3 CanSino Biologicals Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CanSino Biologicals Covid-19 Vaccine Product Portfolio
  12. 8.2.5 CanSino Biologicals Recent Developments
  13. 8.3 Inovio Pharmaceuticals
  14. 8.3.1 Inovio Pharmaceuticals Company Information
  15. 8.3.2 Inovio Pharmaceuticals Business Overview
  16. 8.3.3 Inovio Pharmaceuticals Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio
  18. 8.3.5 Inovio Pharmaceuticals Recent Developments
  19. 8.4 Shenzhen Geno-Immune Medical Institute
  20. 8.4.1 Shenzhen Geno-Immune Medical Institute Company Information
  21. 8.4.2 Shenzhen Geno-Immune Medical Institute Business Overview
  22. 8.4.3 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio
  24. 8.4.5 Shenzhen Geno-Immune Medical Institute Recent Developments
  25. 8.5 GlaxoSmithKine
  26. 8.5.1 GlaxoSmithKine Company Information
  27. 8.5.2 GlaxoSmithKine Business Overview
  28. 8.5.3 GlaxoSmithKine Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKine Covid-19 Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKine Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Covid-19 Vaccine Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Johnson＆Johnson
  38. 8.7.1 Johnson＆Johnson Company Information
  39. 8.7.2 Johnson＆Johnson Business Overview
  40. 8.7.3 Johnson＆Johnson Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson＆Johnson Covid-19 Vaccine Product Portfolio
  42. 8.7.5 Johnson＆Johnson Recent Developments
  43. 8.8 Heat Biologics
  44. 8.8.1 Heat Biologics Company Information
  45. 8.8.2 Heat Biologics Business Overview
  46. 8.8.3 Heat Biologics Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Heat Biologics Covid-19 Vaccine Product Portfolio
  48. 8.8.5 Heat Biologics Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Covid-19 Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Covid-19 Vaccine Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst